Sign in

068270 on Korean Stock Exchange

Celltrion

Logo: 주식회사 셀트리온, Public domain, via Wikimedia Commons3

South Korean biopharmaceutical company

Celltrion, Inc. (Korean: 주식회사 셀트리온) is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Seo Jung-jin, is the richest person in South Korea.2 Its shares trade on Korean Stock Exchange under the symbol 068270.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1999Founded1

Compare with another stock.

  • Ticker068270 on Korean Stock Exchange1
  • HeadquartersIncheon1
  • Websitewww.celltrion.com
  • Legal formjusik hoesa, public company1

See how the biggest companies compare on our leaderboards

Celltrion, Inc. (Korean: 주식회사 셀트리온) is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Seo Jung-jin, is the richest person in South Korea. Seo Jung-jin, its founder was awarded the 2021 EY World Entrepreneur Of The Year.2

Corporate structure

Celltrion sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from subsidiaries, stakes and holdings from Wikidata (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

The story

Founded by Seo Jung-jin in 1999.1

In 1999, Nexol, Inc. (now Celltrion Healthcare Co., Ltd.) was founded as a global business management consulting firm. In 2002, Celltrion, Inc. was founded as a biopharmaceutical company.

In 2008, Nexol and Celltrion established a global distribution agreement.

In 2009, distribution channels were established in America, Oceania, Europe (Hospira) and Nexol, Inc. renamed as Celltrion Healthcare Co., Ltd.

In 2010, distribution channels were established in Japan (Nippon Kayaku), Commonwealth of Independent States (CIS), Eastern Europe, and the Middle East (Egis).

In 2013, distribution channels were added in Europe (Mundipharma, Biogaran, and Kern).

On September 30, 2024, Celltrion completed the establishment of its oversees corporation in Vietnam.

22 Oct. 2024. Celltrion secured a 100.4 billion won ($72.8 million) deal for contract development and manufacturing (CDMO) with TEVA Pharmaceuticals International for the migraine treatment Ajovy.

In November 2024, Celltrion acquired iQone Healthcare Switzerland, a pharmaceutical company for around 30 billion won ($21 million). This move will help its expansion in Europe.

Read the full text

In January 2026, Celltrion began operating the production facility it acquired in 2025 from Eli Lilly in Branchburg, New Jersey. In May, Celltrion acquired French health care firm Gifrer. In June, the company's first union was established.

From Wikipedia’s article on Celltrion, shared under CC BY-SA 4.0.4

Leadership

Who has led Celltrion, and when. Pick a name to see everywhere that person has worked.

Products and brands

  • infliximab

Listed on Wikidata.1

The company's products are manufactured at mammalian cell culture facilities designed and built to comply with the United States FDA’s cGMP, and the European Medicines Agency’s GMP standards.

Inline product

Remsima (infliximab) is a biosimilar monoclonal antibody against tumor necrosis factor alpha (TNF-α), approved by the European Medicines Agency (EMA) for treatment of:

rheumatoid arthritis,

adult Crohn's disease,

Read the full text

pediatric Crohn's disease,

ulcerative colitis,

pediatric ulcerative colitis,

ankylosing spondylitis,

psoriatic arthritis, and

psoriasis.

In 2012 Remsima was approved by the Republic of Korea's Ministry of Food and Drug Safety (MFDS), previously known as Korea Food and Drug Administration and in 2013 it became the world's first biosimilar monoclonal antibody (mAb) approved by the EMA.

Herzuma is a biosimilar trastuzumab approved by the MFDS for treatment of early and advanced (metastatic) HER2+ breast cancer as well as advanced (metastatic) stomach cancer. Herzuma is a HER2+ breast cancer therapy designed to treat aggressive HER positive metastatic and adjuvant breast cancer, as well as HER2 positive adenocarcinoma of the stomach that has spread (metastatic or advanced gastric cancer).

Truxima (previously known as CT-P10) is the first biosimilar of the reference monoclonal antibody rituximab that targets CD20 molecule primarily found on the surface of B-cells. Its target indications are rheumatoid arthritis, non-Hodgkin lymphoma and chronic lymphocytic leukemia. It was approved by the EMA in February 2017.

From Wikipedia’s article on Celltrion, shared under CC BY-SA 4.0.4

Subsidiaries and ownership

Subsidiaries

From Wikidata.1

Timeline

  1. Feb 9, 2018Went public Listed on Korean Stock Exchange1
  2. Jul 19, 2005Went public Listed on KOSDAQ1
  3. 1999Founded Founded1

Calendar

Drug trials and FDA: coming up

  1. Dec 2026Phase 3 trial readout expected Phase 3 trial of Metformin, Alogliptin and others in T2DM: primary completion expected Dec 2026 (ClinicalTrials.gov NCT07093476).5
  2. Feb 2027Phase 3 trial readout expected Phase 3 trial of CT-P53, US-Ocrevus and others in Relapsing-remitting Multiple Sclerosis: primary completion expected Feb 2027 (ClinicalTrials.gov NCT05906992).6
  3. Feb 2027Phase 3 trial readout expected Phase 3 trial of CT-P51 and EU-approved Keytruda in Non Squamous Non Small Cell Lung Cancer: primary completion expected Feb 2027 (ClinicalTrials.gov NCT06939595).7
  4. Mar 8, 2027Phase 3 trial readout expected Phase 3 trial of CT-P44(Daratumumab) and Darzalex Faspro(Daratumumab) in Refractory or Relapsed Multiple Myeloma: primary completion expected Mar 8, 2027 (ClinicalTrials.gov NCT06952478).8

Drug trials and FDA: recently

  1. Apr 16, 2026Phase 3 trial completed Phase 3 trial of CT-L03 Group 1, CT-L03 Group 2 and others in T2DM: primary completion Apr 16, 2026, no results posted yet (ClinicalTrials.gov NCT06571591).9
  2. Feb 18, 2026Phase 3 trial completed Phase 3 trial of CT-P55 and EU-approved Cosentyx in Plaque Psoriasis: primary completion Feb 18, 2026, no results posted yet (ClinicalTrials.gov NCT06630559).10
  3. Jan 21, 2026FDA approval FDA approved Avtozma (tocilizumab-anoh), a biologic (BLA 761498).11
  4. Oct 29, 2025FDA approval FDA approved Osenvelt (denosumab-bmwo), a biologic (BLA 761404).12
  5. Oct 2, 2025FDA approval FDA approved Eydenzelt (aflibercept-boav), a biologic (BLA 761377).13
  6. Apr 30, 2025FDA approval FDA approved Steqeyma (ustekinumab-stba), a biologic (BLA 761338).14
  7. Mar 7, 2025FDA approval FDA approved Omlyclo (omalizumab-igec), a biologic (BLA 761399).15

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15